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Abstract
Uterine leiomyoma (UL) is the most common benign smooth muscle cell tumor with 
as yet unknown etiology and pathogenesis. This study was carried out to investigate 
the association of ESR1-351 A>G, ESR1 -397 T>C and CYP1A1 (Ile462Val) poly-
morphisms with UL in female patients of Iranian origin. In this case-control study, 
276 patients with UL and 156 healthy women were recruited. The genetic polymor-
phisms ESR1-351 A>G, ESR1-397 T>C and CYP1A1 (Ile462Val) were genotyped by 
polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP). 
No significant difference were found in frequencies of both genotypes and alleles of 
ESR1-351 A>G, ESR1-397 T>C and CYP1A1 (Ile462Val) polymorphisms between 
the two groups (p>0.05). Our findings indicated that these ESR1 and CYP1A1 poly-
morphisms were not associated with the development of UL in the cases reported 
here.
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Uterine leiomyoma (UL) or fibroid is the most 
common pelvic benign tumor with a prevalence 
of 25% among women in the reproductive age 
and 50% in autopsy reports (1). Pathological in-
vestigations have revealed its existence in 73 and 
84% of women during premenopause and meno-
pause stages respectively (2). These tumors are the 
most frequent cause of hysterectomy and uterine 
surgery. They lead to a variety of symptoms in-
cluding menstural abnormalities, pelvic pain, in-
fertility and spontaneous abortion (3). Despite the 
high prevalence of the tumors, exact mechanisms 
of their initiation and growth remain unclear. Evi-
dence indicates that the growth and the develop-
ment of UL are estrogen-dependent (4, 5). It has 
been shown that there is some difference between 
leyomyoma and normal myometrium in terms of 
estrogen regulation of gene expression (6), and 
that leiomyoma tissue is more sensitive to estro-
gen compared with myometrium.  Binding of es-
trogen to estrogen receptors generate signals in the 
target cells which prompts cellular proliferation 
and in the presence of ESR1 has an anti-apoptot-
ic effect (7). It could also act as a procarcinogen 
through metabolic processes and induce genotox-
icity (8). Several polymorphisms in ESR1,  located 
on chromosome 6 (6q24-26), have been reported 
to be related to gene expression and protein func-
tion. There are two well-known polymorphisms in 
ESR1, ESR1 (XbaI) and ESR1 (PvuII) both in in-
tron 1 (8, 9). The first step of estrogen metabolism 
is hydroxylation which is catalyzed by cytochrome 
P450 1A1 (CYP1A1), a member of cytochrome 
P450 enzymes (10). CYP1A1 also catalyzes 2-hy-
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droxy catechol, an estrogen metabolite with no es-
trogenic activity. In parallel, in another mutually 
exclusive pathway 16α-hydroxylation produces 
metabolites with strong estrogenic properties (11). 
Polymorphisms in CYP1A1 may affect the activity 
of the produced enzyme and contribute to the etiol-
ogy of leiomyoma. A common variant in this gene 
is A>G in codon 462 (Ile462Val). Association be-
tween Ile462Val polymorphism and UL has been 
reported in the Chinese women (12). In homozy-
gous state, the polymorphism has been thought 
to increase the activity of CYP1A1 enzyme (13). 
The current case-control study was conducted to 
examine the hypothesis that ESR1-351(XbaI), 
ESR1-397(PvuII) and CYP1A1 (Ile462Val) poly-
morphisms are associated with the development of 
uterine leiomyoma in female patients from Char-
mahal and  Bakhtiari province of Iran.
In this case-control study, we investigated 276 
women diagnosed with UL at the Department of Gy-
necology at Shahrekord Hajar Hospital from 2010 to 
2011. UL was diagnosed by transvaginal sonographic 
examination and confirmed by histological test after 
myomectomy or hysterectomy. All the participants 
were at reproductive age. The mean age of the sub-
jects was 44 ± 5.7 years, and the mean body mass 
index (BMI) was 27.5 ± 4.2 kg/m2. The healthy con-
trol group included 157 women without any evidence 
of leiomyoma according to transvaginal ultrasound 
exam. There were no differences between the case 
and control groups in terms of age, BMI, ethnicity and 
menarche. Cases with genital tract neoplasms, abnor-
mal uterine bleeding, adenomyosis, pregnancy, ESR1 
dependent cancers, rheumatoid arthritis, alcohol in-
take, permanent or recent use of oral contraceptives 
and smoking habit were excluded from the study. 
Informed consent was obtained from all participants 
before their incorporation in the study. The Ethics 
Committees of the Shahrekord University of Medical 
Sciences approved all procedures.
Genomic DNA was extracted from blood samples 
using a standard phenol/chloroform extraction meth-
od. The quality of DNA was evaluated by spectro-
photometry for all the samples. ESR1 -351 XbaI A/G 
and -397 PvuII T/C polymorphisms were assayed by 
the method of polymerase chain reaction (PCR) fol-
lowed by restriction fragment length polymorphism 
(RFLP). PCR amplification was performed using 
primers formerly reported (12, 14).
Table 1 summarizes the primer sequences, PCR 
conditions, restriction enzymes, digestion prod-
ucts and their lengths. PCR and digestion products 
were separated by vertical non-denaturing 8% po-
lyacrylamide gel and visualized by silver staining. 
To confirm the genotyping results, a subset of PCR 
products were examined by DNA sequencing, and 
the results were 100% concordant. 
Table 1: The primer sequences, PCR conditions and Restriction enzymes for ESR1-351 A/G and -397 T/C and CYP1A1gene 
polymorphisms
product sizes(bp)Restriction 
enzyme  
Annealing     
temp (˚C/s)  
Primers                                       Polymorphism 
ESR1-351 (14)              
GG genotype: 1374bpXbaI 60/40 F:5´CTGCCACCCTATCTGTATCTTTTCCTATTCTCC -3´        A/G XbaI  
AA genotype: 982+ 392bpR:5´-TCTTTCTCTGCCACCCTGGCGTCGATTATCTGA-3´
AG genotype: 1374+982+392bp
TT genotype: 1374bpPvuII60/40            F:5´-CTGCCACCCTATCTGTATCTTTTCCTATTCTCC
R:5´-TCTTTCTCTGCCACCCTGGCGTCGATTATCTGA-3´
ESR1-397 (14)               
CC genotype:937+ 437bpF:5´-CTGCCACCCTATCTGTATCTTTTCCTATTCTCC
R:5´-TCTTTCTCTGCCACCCTGGCGTCGATTATCTGA-3´
 T /C PvuII
TC genotype: 1374+937+437bp
AA genotype: 139bpHincII60/60             F:5´-GATCTGAGTTCCTACCTGA-3´CYP1A1 (12)
AG genotype: 139+116+ 23bpR:5´-AAGAGAAAGACCTCCCAGCGGTCAA-3´                         Ile462Val (A/G)     
References are given in parentheses after each polymorphism. F and R indicate forward and reverse primers.
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Genotypes and allelic frequencies for indi-
vidual polymorphisms were compared between 
cases and controls using the X2-test. P<0.05 
was considered statistically significant. Hardy-
Weinberg equilibrium was tested with a good-
ness of fit X2-test with one degree of freedom 
to compare the observed genotype frequencies 
with the expected genotype frequencies. The 
associations between both alleles and geno-
types and disease risk were calculated using 
odds ratios (OR) with a 95% confidence inter-
val (CI).
The allele and genotype frequencies of  ESR1-
351A/G in the case and control groups are given 
in table 2. The proportion of women homozy-
gous for the A allele (AA), heterozygous (AG), 
and homozygous for the G allele (GG) were 
32.7, 46.4 and 19.9%, respectively in the leio-
myoma group, and 35.1, 49, and 15.9%, respec-
tively in the control group. These frequencies 
are not significantly different between the two 
groups. The ESR1-397T/C allele and genotype 
frequencies of women with UL and controls are 
shown in table 3. The allele frequencies for T 
and C alleles were not significantly different 
between the case and control groups (p=0.386) 
(Table 2).
The CYP1A1 (Ile462Val) polymorphism fre-
quencies in the control and UL patient groups 
are given in table 3. The AG genotype frequen-
cies were 12.7 and 8.3% in the patients and 
controls, respectively. The allele frequencies 
for A and G alleles were 0.94 and 0.06% in the 
leiomyoma and 0.96% and not significantly 
different between the UL and control groups 
(p=0.174, Table 2).
Table 2: TAllele frequencies of ESR1-351 A/G and ESR1-397 T/C gene polymorphisms in women with leiomyoma and normal 
controls
P valueOR (95% CI)Control n=157                   Cases n=276            Polymorphism           
No (%) No (%)
ESR1 -351 A/G Genotype frequency
1.00 (ref)55 (35.1)93 (32.7)AA
0.9390.938 (0.635-1.52)77 (49)128 (46.4)AG
0.3721.31 (0.73-2.32)25 (15.9)55 (19.9)GG
ESR1 -351 A/G Allele frequency
1.00 (ref)187 (59.6)314 (56.9) A
0.4441.112 (0.842-1.479)127(40.4)238 (43.1)G
ESR1-397 T/C Genotype frequency
1.00 (ref)50 (31.8)78 (28.3)TT 
0.5421.152 (0.731-1.816)74 (47.2)133 (48.2)TC
0.4051.223 (0.729-2.187)33 (21)65 (23.5)CC
ESR1-397 T/C Allele frequency
1.00 (ref)174 (0.55)289 (0.52)T
0.3861.13 (0.856-1.494)140 (0.45)263 (0.48)C
 CELL JOURNAL(Yakhteh), Vol 16, No 2, Summer 2014 228
ESR1 and CYP1A1 and UL
Table 3: The genotype and allele frequencies of polymorphisms of CYP1A1 Ile462Val gene in women with leiomyoma and 
normal controls
P valueOR (95% CI)Control n=157                   Cases n=276            CYP1A1            
No (%) No (%)Genotypes
Genotype frequency
1.00 (ref)144 (91.7)241 (87. 3)AA
0.1061.609 (0.824-3.141)13 (8.3)35 (12.7)AG
Allele frequency
1.00 (ref)301(0.96)517 (0.94) A
0.1741.567 (0.816 -3.009)13 (0.04)35 (0.06)G
OR; Odds ratio, 95% CI 95% confidence interval and  ref; Reference.
Our results did not show significant differ-
ence in allelic and genotypic distribution of CY-
P1A1 Ile462Val polymorphism between the two 
groups. So far, contradictory results have been 
reported as regard to the specified polymor-
phisms and the risk of estrogen related diseases. 
Results of the present study are in accordance 
with some of these studies. In a study by Rosa 
et al. (15) no association between CYP17A1 and 
CYP19 gene polymorphisms and UL were ob-
served. Shin et al. (16) did not find any associa-
tion between CYP1A1 MspI gene polymorphism 
and breast cancer risk in Korean women either. 
However, our findings conflict with previously 
published findings in Chinese, Egyptian and 
Caucasian women reporting an association be-
tween CYP1A1 polymorphism and UL (12, 14, 
17, 18).
In the study on ESR1 gene, no significant as-
sociation were observed between either allele 
frequency or genotype distribution of ESR1-
351A>G and ESR1-397T>C polymorphisms 
and UL. Various studies have shown that ESR1 
(XbaI) and ESR1 (PvuII) polymorphisms are 
associated with many estrogen-dependent dis-
eases, such as early menarche (18), breast can-
cer (19), osteoporosis (20), prostate cancer (21), 
endometriosis and adenomyosis (22). Hsieh et 
al. (14) showed that there was an association 
between ESR1 (XbaI) and ESR1(PvuII) and UL 
risk in the Chinese women. In contrast, Villano-
va et al. (23) failed to observe any significant 
association between ESR1 polymorphisms and 
UL in Brazilian women. The underlying source 
of discrepancies in the results among different 
studies could partly be the differences in genet-
ic background among the studied populations. 
It is also possible that estrogen receptor gene 
polymorphisms are differentially in linkage dis-
equilibrium with an as yet unknown functional 
variant that influences leiomyoma susceptibil-
ity (14). Besides, Leiomyoma is a complicated 
phenotype and different pathways may lead to 
its pathogenesis. Thus far, many risk factors 
such as age, premature menstruation, obesity, 
nulliparity, lifestyle and ethnicity have been 
known for disease pathogensis (24). Ethnicity 
is said to play a significant role in genetic regu-
lation of estrogen, ER action and association of 
polymorphism to particular disease (25). There-
fore, it is not surprising to find that ESR1 poly-
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morphisms have no association in some ethnic 
groups.
Thus, the investigated polymorphisms seem to 
have no role in the genetic susceptibility of the 
tumors in the studied subjects. Furthermore, the 
subtypes of the UL were not determined in this 
study.  Further studies are needed to identify the 
possible different etiology of the UL subtypes. 
Also, role of gene-environment interactions in 
the pathogenesis of UL should be investigated.
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